ascopubs.org

Repurposing hemostatic drug desmopressin in AVPR2-expressing triple-negative breast cancer: Target expression analysis and preclinical antineoplastic effects on tumor growth ...

Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Monthly Prescribing Reference

FDA to Review Oral Solution Formulation of Desmopressin

The FDA has assigned a Prescription Drug User Fee Act target date of February 25, 2026 to the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ET-600 ...
Nasdaq

FDA Accepts Eton Pharma's NDA For ET-600 Desmopressin Oral Solution

(RTTNews) - Eton Pharmaceuticals, Inc (ETON) Tuesday said that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ET-600, a proprietary desmopressin ...